Reneuron Group Plc (RNUGF) 0.0540 $RNUGF
Global Retinitis Pigmentosa (Retinitis) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqkpbq/retinitis) has announced the addition of the "Global Retinitis Pigmentosa (Retinitis) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - QLT Inc. - Sanofi - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Acucela Inc. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - California Stem Cell, Inc. - Amarantus Bioscience Holdings, Inc. - GenSight Biologics Drug Profiles - unoprostone isopropyl - NT-501 - Recombinant Human Nerve Growth Factor - valproic acid - UshStat - QLT-091001 - rAAV2-VMD2-hMERTK - Gene Therapy for Retinitis Pigmentosa and Glaucoma - Mesenchymal Stem Cell - emixustat hydrochloride - BDM-E - AMRS-001 - ReN-003 - Gene Therapy To Activate RPGR For X-Linked Retinitis Pigmentosa - RST-001 - Cyclic Nucleotide Analogue - GT-038 - Retinal Pigment Epithelial Progenitor Cells for Ophthalmology - Gene Therapy For Ophthalmology - proinsulin human SR - PRO-015 - Small Molecule for Retinitis Pigmentosa - FIB-111 - Compound-9 - Optogenetic Therapy for Retinitis Pigmentosa - norgestrel - CB-11 - Drug for Retinitis Pigmentosa - BNP-RP - Small Molecules for CNS Disorders and Ophthalmology - Small Molecule To Agonize Neurotrophin Receptor For Retinitis Pigmentosa - tetracaine - Compound-5 - Small Molecules Targeting Nuclear Receptors for Retinitis Pigmentosa - Gene Therapy For Ocular Diseases - Stem Cell Derived Three-Dimensional (3D) Retinal Tissue for Ophthalmology - Stem Cell Therapy for Retinitis Pigmentosa Companies Mentioned: - QLT Inc. - Sanofi - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Acucela Inc. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - California Stem Cell, Inc. - Amarantus Bioscience Holdings, Inc. - GenSight Biologics For more information visit http://www.researchandmarkets.com/research/xqkpbq/retinitis
Latest Retinitis Pigmentosa (Retinitis) Pipeline Review
M2 - Tue Jan 28, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/cjq6dr/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013" report to their offering. 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis). Scope - A snapshot of the global therapeutic scenario for Retinitis Pigmentosa (Retinitis). - A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Retinitis Pigmentosa (Retinitis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - QLT Inc. - Sanofi - Sangamo BioSciences, Inc. - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - Amarantus Bioscience Holdings, Inc. - ProRetina Therapeutics, S.L - RetroSense Therapeutics, LLC - GenSight Biologics For more information visit http://www.researchandmarkets.com/research/cjq6dr/retinitis
Global Stem Cell Market Report 2013
M2 - Tue Dec 17, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/qsfq7f/stem_cell_markets) has announced the addition of the "Global Stem Cell Market Report 2013" report to their offering. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells. However, recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders. Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential. "Global Stem Cell Market Report 2013", describes the specific market segments of the medical research space using stem cells for research and development (R&D) purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells. Key Topics Covered: 1. Overview 2. Biology of Stem Cells 3. Stem Cell Therapy 4. Market Analysis of the Stem Cell Space 5. Strategic Roadmap to Cell Therapy Industry 6. Funding for Regenerative Medicine Research 7. Current Stem Cell Research 8. Company Profiles Companies Mentioned: - Athersys, Inc - Brainstorm Cell Therapeutics, Inc - CryoLife, Inc - Epistem PLC - Forticell Bioscience, Inc - Glycosan Biosystems, Inc - Humacyte, Inc - International Stem Cell Corporation - Japan Tissue Engineering Co., Ltd - LifebankUSA - Miltenyi Biotec - Novocell, Inc - Osiris Therapeutics, Inc - Pluristem Therapeutics, Inc - ReNeuron Group Plc - Stempeutics Research Private Limited - Tengion, Inc - VistaGen Therapeutics, Inc - ZenBio, Inc For more information visit http://www.researchandmarkets.com/research/qs...ll_markets
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013 Out Now
M2 - Thu Aug 08, 11:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2j8flq/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). - A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AnGes MG, Inc. - Arena Pharmaceuticals, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - Athersys, Inc. - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Cytokinetics, Inc - DNAVEC Corporation - Diffusion Pharmaceuticals LLC - F. Hoffmann-La Roche Ltd. - Medistem, Inc. - Mesoblast Ltd - miRagen Therapeutics, Inc. - Nissan Chemical Industries, Ltd. - Proteon Therapeutics, Inc. - ReNeuron Group plc - RegenoCELL Therapeutics, Inc. - Sigma-Tau S.p.A. - Synthon BV - Theravasc, Inc. - Viromed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2j8flq/peripheral About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Occlusive Arterial Disease (OAD) - Latest Pipeline Review Report
M2 - Thu Jul 11, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4klnnk/occlusive) has announced the addition of the "Occlusive Arterial Disease (OAD) - Pipeline Review, H2 2012" report to their offering. 'Occlusive Arterial Disease (OAD) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Occlusive Arterial Disease (OAD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Occlusive Arterial Disease (OAD). Scope - A snapshot of the global therapeutic scenario for Occlusive Arterial Disease (OAD). - A review of the Occlusive Arterial Disease (OAD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till regis
Regenerative Medicine Markets - 2013 Report
M2 - Mon Jun 24, 4:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6v4tt2/regenerative) has announced the addition of the "Regenerative Medicine Markets" report to their offering. Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement. This TriMark Publications report discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures. The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions. Key Topics Covered 1. Overview
Retinitis Pigmentosa (Retinitis) - Pipeline Review Report, H1 2013 Edition
M2 - Tue Jun 04, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hpnhmf/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2013" report to their offering. 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis). Scope - A snapshot of the global therapeutic scenario for Retinitis Pigmentosa (Retinitis). - A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till regis
Ischemic Stroke - Pipeline Review, H1 2013 Report Profiles Players such as Eli Lilly and Company and SynZyme Technologies, LLC
M2 - Mon Apr 29, 11:16AM CDT
Research and Markets has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Ischemic Stroke - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Ischemic Stroke. - A review of the Ischemic Stroke products under development by c
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2013
M2 - Wed Apr 17, 4:23AM CDT
Research and Markets has announced the addition of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2013 report to their offering. 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
Stroke - Pipeline Review, H1 2013
M2 - Thu Mar 21, 4:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nswlxr/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Stroke - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Stroke. Scope - A snapshot of the global therapeutic scenario for Stroke. - A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the
Stem Cell Approaches in Neurology and Psychiatry: 25 Trend Setters for 2013 - 3rd Biennial Report
M2 - Fri Dec 21, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/5s39hx/stem_cell) has announced the addition of NeuroInsights's new report "Stem Cell Approaches in Neurology and Psychiatry: 25 Trend Setters for 2013 - 3rd Biennial Report" to their offering. An Industry Insider Report on Innovative Research and Development in Stem Cell Technology for the Central Nervous System Stem cell approaches in neurology and psychiatry is the focus of a new report released today by NeuroInsights, the neurotech market authority. The industry insider report on innovative research and development in stem cell technology for the brain and nervous system provides unique insights into the key players, cutting edge science and investment opportunities in this rapidly advancing field. Stem cell companies focused on the central nervous system (CNS) have the potential to address some of the largest unmet healthcare markets including: Alzheimer's disease, amyotrophic lateral sclerosis, depression, hearing loss, Huntington's d
Global Retinitis Pigmentosa (Retinitis) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqkpbq/retinitis) has announced the addition of the "Global Retinitis Pigmentosa (Retinitis) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - QLT Inc. - Sanofi - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Acucela Inc. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - California Stem Cell, Inc. - Amarantus Bioscience Holdings, Inc. - GenSight Biologics Drug Profiles - unoprostone isopropyl - NT-501 - Recombinant Human Nerve Growth Factor - valproic acid - UshStat - QLT-091001 - rAAV2-VMD2-hMERTK - Gene Therapy for Retinitis Pigmentosa and Glaucoma - Mesenchymal Stem Cell - emixustat hydrochloride - BDM-E - AMRS-001 - ReN-003 - Gene Therapy To Activate RPGR For X-Linked Retinitis Pigmentosa - RST-001 - Cyclic Nucleotide Analogue - GT-038 - Retinal Pigment Epithelial Progenitor Cells for Ophthalmology - Gene Therapy For Ophthalmology - proinsulin human SR - PRO-015 - Small Molecule for Retinitis Pigmentosa - FIB-111 - Compound-9 - Optogenetic Therapy for Retinitis Pigmentosa - norgestrel - CB-11 - Drug for Retinitis Pigmentosa - BNP-RP - Small Molecules for CNS Disorders and Ophthalmology - Small Molecule To Agonize Neurotrophin Receptor For Retinitis Pigmentosa - tetracaine - Compound-5 - Small Molecules Targeting Nuclear Receptors for Retinitis Pigmentosa - Gene Therapy For Ocular Diseases - Stem Cell Derived Three-Dimensional (3D) Retinal Tissue for Ophthalmology - Stem Cell Therapy for Retinitis Pigmentosa Companies Mentioned: - QLT Inc. - Sanofi - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Acucela Inc. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - California Stem Cell, Inc. - Amarantus Bioscience Holdings, Inc. - GenSight Biologics For more information visit http://www.researchandmarkets.com/research/xqkpbq/retinitis
Latest Retinitis Pigmentosa (Retinitis) Pipeline Review
M2 - Tue Jan 28, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/cjq6dr/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013" report to their offering. 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis). Scope - A snapshot of the global therapeutic scenario for Retinitis Pigmentosa (Retinitis). - A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Retinitis Pigmentosa (Retinitis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - QLT Inc. - Sanofi - Sangamo BioSciences, Inc. - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - Amarantus Bioscience Holdings, Inc. - ProRetina Therapeutics, S.L - RetroSense Therapeutics, LLC - GenSight Biologics For more information visit http://www.researchandmarkets.com/research/cjq6dr/retinitis
Global Stem Cell Market Report 2013
M2 - Tue Dec 17, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/qsfq7f/stem_cell_markets) has announced the addition of the "Global Stem Cell Market Report 2013" report to their offering. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells. However, recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders. Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential. "Global Stem Cell Market Report 2013", describes the specific market segments of the medical research space using stem cells for research and development (R&D) purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells. Key Topics Covered: 1. Overview 2. Biology of Stem Cells 3. Stem Cell Therapy 4. Market Analysis of the Stem Cell Space 5. Strategic Roadmap to Cell Therapy Industry 6. Funding for Regenerative Medicine Research 7. Current Stem Cell Research 8. Company Profiles Companies Mentioned: - Athersys, Inc - Brainstorm Cell Therapeutics, Inc - CryoLife, Inc - Epistem PLC - Forticell Bioscience, Inc - Glycosan Biosystems, Inc - Humacyte, Inc - International Stem Cell Corporation - Japan Tissue Engineering Co., Ltd - LifebankUSA - Miltenyi Biotec - Novocell, Inc - Osiris Therapeutics, Inc - Pluristem Therapeutics, Inc - ReNeuron Group Plc - Stempeutics Research Private Limited - Tengion, Inc - VistaGen Therapeutics, Inc - ZenBio, Inc For more information visit http://www.researchandmarkets.com/research/qs...ll_markets
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013 Out Now
M2 - Thu Aug 08, 11:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2j8flq/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). - A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AnGes MG, Inc. - Arena Pharmaceuticals, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - Athersys, Inc. - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Cytokinetics, Inc - DNAVEC Corporation - Diffusion Pharmaceuticals LLC - F. Hoffmann-La Roche Ltd. - Medistem, Inc. - Mesoblast Ltd - miRagen Therapeutics, Inc. - Nissan Chemical Industries, Ltd. - Proteon Therapeutics, Inc. - ReNeuron Group plc - RegenoCELL Therapeutics, Inc. - Sigma-Tau S.p.A. - Synthon BV - Theravasc, Inc. - Viromed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2j8flq/peripheral About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Occlusive Arterial Disease (OAD) - Latest Pipeline Review Report
M2 - Thu Jul 11, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4klnnk/occlusive) has announced the addition of the "Occlusive Arterial Disease (OAD) - Pipeline Review, H2 2012" report to their offering. 'Occlusive Arterial Disease (OAD) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Occlusive Arterial Disease (OAD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Occlusive Arterial Disease (OAD). Scope - A snapshot of the global therapeutic scenario for Occlusive Arterial Disease (OAD). - A review of the Occlusive Arterial Disease (OAD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till regis
Regenerative Medicine Markets - 2013 Report
M2 - Mon Jun 24, 4:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6v4tt2/regenerative) has announced the addition of the "Regenerative Medicine Markets" report to their offering. Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement. This TriMark Publications report discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures. The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions. Key Topics Covered 1. Overview
Retinitis Pigmentosa (Retinitis) - Pipeline Review Report, H1 2013 Edition
M2 - Tue Jun 04, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hpnhmf/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2013" report to their offering. 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis). Scope - A snapshot of the global therapeutic scenario for Retinitis Pigmentosa (Retinitis). - A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till regis
Ischemic Stroke - Pipeline Review, H1 2013 Report Profiles Players such as Eli Lilly and Company and SynZyme Technologies, LLC
M2 - Mon Apr 29, 11:16AM CDT
Research and Markets has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Ischemic Stroke - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Ischemic Stroke. - A review of the Ischemic Stroke products under development by c
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2013
M2 - Wed Apr 17, 4:23AM CDT
Research and Markets has announced the addition of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2013 report to their offering. 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
Stroke - Pipeline Review, H1 2013
M2 - Thu Mar 21, 4:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nswlxr/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Stroke - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Stroke. Scope - A snapshot of the global therapeutic scenario for Stroke. - A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the
Stem Cell Approaches in Neurology and Psychiatry: 25 Trend Setters for 2013 - 3rd Biennial Report
M2 - Fri Dec 21, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/5s39hx/stem_cell) has announced the addition of NeuroInsights's new report "Stem Cell Approaches in Neurology and Psychiatry: 25 Trend Setters for 2013 - 3rd Biennial Report" to their offering. An Industry Insider Report on Innovative Research and Development in Stem Cell Technology for the Central Nervous System Stem cell approaches in neurology and psychiatry is the focus of a new report released today by NeuroInsights, the neurotech market authority. The industry insider report on innovative research and development in stem cell technology for the brain and nervous system provides unique insights into the key players, cutting edge science and investment opportunities in this rapidly advancing field. Stem cell companies focused on the central nervous system (CNS) have the potential to address some of the largest unmet healthcare markets including: Alzheimer's disease, amyotrophic lateral sclerosis, depression, hearing loss, Huntington's d
